Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)

详细信息    查看全文

• 作者：Henning Grø ; nbæ ; k¹ ; ^{Henngroe@rm.dk" class="auth_mail" title="E-mail the corresponding author} ; Sidsel Rø ; dgaard-Hansen² ; Niels Kristian Aagaard¹ ; Vicente Arroyo³ ; Sø ; ren K. Moestrup⁴ ; Elisabet Garcia³ ; Elsa Solà ; ⁵ ; Marco Domenicali⁶ ; Salvatore Piano⁷ ; Hendrik Vilstrup¹ ; Holger Jon Mø ; ller² ; on behalf of the CANONIC study investigators of the EASL-CLIF Consortium
• 关键词：Acute-on-chronic liver failure ; Cirrhosis ; Macrophages ; CD163 ; Mannose receptor ; Cirrhosis complications ; Biomarker ; Prognosis
• 刊名：Journal of Hepatology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：64
• 期：4
• 页码：813-822
• 全文大小：899 K

文摘

Activation of liver macrophages plays a key role in liver and systemic inflammation and may be involved in development and prognosis of acute-on-chronic liver failure (ACLF). We therefore measured the circulating macrophage activation markers soluble sCD163 and mannose receptor (sMR) and related them to the short-(1–3 months) and long-term (6 months) mortality in the cirrhosis patients of the CANONIC study.

Methods

Eighty-six cirrhosis patients had no ascites and no ACLF, 580 had ascites but no ACLF; 100, 66, and 19 had ACLF-grade-I (ACLF-I), ACLF-II, and ACLF-III, respectively. The patients’ clinical course was registered and their MELD, CLIF-C Acute Decompensation (AD), and CLIF-C ACLF-scores computed at inclusion.

Results

We found a stepwise increase (p <0.001) in median sCD163 (5.68 (IQR: 3.86–9.60); 8.26 (5.02–12.34); 9.50 (5.37–17.91); 15.68 (10.12–19.42); 20.18 (15.26–32.20) mg/L) and sMR (0.60 (0.40–0.84); 0.81 (0.57–1.12); 0.81 (0.61–1.26); 1.17 (0.89–1.62); 1.41 (1.14–1.79) mg/L) with increasing grades of ACLF. Both sCD163 and sMR were independently associated with short and long-term mortality and showed equal or higher predictive accuracy than MELD, CLIF-C ACLF and CLIF-C AD scores. Addition of the macrophage markers to the clinical scores improved the prognostic efficacy: In ACLF patients sCD163 improved prediction of short-term mortality (C-index: 0.74 (0.67–0.80)) and in patients without ACLF sMR improved prediction of long-term mortality (C-index: 0.80 (0.76–0.85)).

Conclusions

The severity related increase in sCD163 and sMR and close association with mortality suggest a primary importance of inflammatory activation of liver macrophages in the emergence and course of ACLF. Accordingly, supplementation of the macrophage biomarkers to the platform of the clinical scores improved the prognostic performance beyond that of the original scores.